Efficacy and Safety Outcomes of CAR T-Cell Therapies in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Who Received Prior Treatment with Mosunetuzumab
Abstract
Background: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody that is being evaluated in patients with select B-cell non-Hodgkin lymphoma (B-NHL) histologies in a Phase I/II clinical trial (NCT02500407). Mosunetuzumab is approved by the FDA and EMA for the treatment of patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior lines of systemic therapy. A key emerging question is the optimal treatment sequence of mosunetuzumab and CD19-targeted chimeric antigen receptor (CAR) T-cell therapies, and whether CAR T-cell therapies remain clinically active post mosunetuzumab treatment. Previous data are limited but have shown that the efficacy of CAR T-cell therapies is preserved in patients with B-NHL who progressed following treatment with bispecific antibodies (Crochet et al. Blood 2022; Iacoboni et al. Blood 2023). Here, we present a US multicenter, retrospective, case series to explore the outcomes of patients with R/R B-NHL treated with CAR T-cell therapy after prior mosunetuzumab treatment.
Methods: Patients from a Phase I/II clinical trial (NCT02500407) were included in this analysis, including patients across dose-escalation cohorts. Efficacy and safety outcomes were investigated in patients with R/R B-NHL who received CAR T-cell therapy for the first time following mosunetuzumab treatment. Eligible patients were treated with CAR T-cell therapy between March 21, 2019 and June 7, 2021.
Results: At data cut-off (May 2, 2023), 26 patients…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 26 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.